Clinical Perspective on Clinical Outcome Assessments in Neurosarcoidosis

Abstract Background : There are no validated clinical outcome assessments (COAs) used in neurosarcoidosis. Objective : We surveyed clinicians who treat patients with neurosarcoidosis to determine: 1) current approaches to assessment of neurologic impairment, and 2) clinicians’ needs regarding future COA development. Methods : Physician contacts from the Foundation for Sarcoidosis Research and Neurosarcoidosis Consortium Group were sent an online survey. Results : For 43/143 responders, COAs were used in a minority of settings. Apart from time for administration, the biggest barriers to implementation were lack of validated, disease-specific measures. Conclusions : Lack of validated, disease-specific measures is a barrier to monitoring neurological impairment in neurosarcoidosis.